VanEck Video Gaming and eSports ETF vs Medpace Holdings Inc — how do they compare? VanEck Video Gaming and eSports ETF trades at $100.11 (market cap $248.06M), while Medpace Holdings Inc trades at $612.05 (market cap $16.82B). The key difference: Medpace Holdings Inc is far larger — about 67.8× VanEck Video Gaming and eSports ETF's market cap, and Medpace Holdings Inc is trading nearer its 52-week high, VanEck Video Gaming and eSports ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold VanEck Video Gaming and eSports ETF for 66 Days and Medpace Holdings Inc for 14 Days on average.
| ESPO | MEDP | |
|---|---|---|
Market Cap | $248.06M | $16.82B |
Volume | 13,622 | 223,093 |
Sector | Sector/Thematic | Health |
52-Week High | $118.68 | $630.19 |
52-Week Low | $85.25 | $393.42 |
Typical Hold Time | 66 Days | 14 Days |
Enterprise Value | — | $16.44B |
Signals from Pluang's Aura AI — not financial advice
ESPO stock shows strong technical momentum, gaining 2.87% to $100.11 with a bullish moving average signal. The stock trades near resistance levels at $98-$99 while maintaining support at $97. Technical indicators show mixed signals with neutral RSI readings but positive ADX momentum. Fundamental data remains limited pending updated financial disclosures.
The technical setup suggests near-term upside potential if resistance levels are breached, though limited fundamental visibility warrants caution. Key risks include lack of recent financial data and market volatility. Investors require updated earnings reports and analyst coverage for proper valuation assessment before establishing positions.
MEDP trades at $612.05, up 1.29% today, near its consensus price target of $620.44. The stock shows strong profitability with a 17.67% net margin and has beaten earnings estimates for the last three quarters. Technical indicators are neutral overall, with support at $595 and resistance at $612. Recent news highlights CEO stock sales and institutional position changes, while the company prepares to report Q3 2026 results on October 21.
Outlook remains positive given consistent earnings beats and projected revenue growth to $2.8B in 2026. Risks include high valuation multiples (P/E 35.41) and insider selling. Analyst consensus is cautious with 79% hold ratings, suggesting limited near-term upside but solid fundamental support for long-term holders.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
ESPO is a thematic ETF that invests in the global video gaming and eSports industry. It provides exposure to companies involved in game development, hardware, and streaming, including major firms like Tencent, Nintendo, and Electronic Arts.
Read more on ESPO →Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →